Companies › TrueBinding
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TB006 | – | Phase 2 | Parkinson's Disease (PD); Autism Spectrum Disorder | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06773962 | TB006 | Phase 2 | Parkinson's Disease (PD) | Neurology | Nov 2026 |
| NCT06500637 | TB006 | Phase 2 | Autism Spectrum Disorder | Psychiatry | Dec 2026 |
No annotated target.
–
Reunion Neuroscience Noema Pharma Spinogenix Shanghai Auzone Biological Technology MapLight Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.